Randomized Controlled Study on T-PEP Versus IPV Method for Lower Respiratory Airways Clearance in Tetraplegic Tracheotomized Spinal Cord Injured Patients (T-PEP)
Spinal Cord Injury Cervical
About this trial
This is an interventional treatment trial for Spinal Cord Injury Cervical focused on measuring Lower respiratory airways clearance, Deep lung clearance, Secretions overproduction, Positive Expiratory Pressure, Intrapulmonary Percussive Ventilation, Tetraplegia, Tracheotomy, Critical Care Unit, Mechanical ventilation, Respiratory physiotherapy
Eligibility Criteria
Inclusion Criteria:
- spinal cord injury due to traumatic or non-traumatic etiology;
- neurological level from C4 to C7 (included)
- complete spinal cord injury, classifiable as "A" grade according to the Asia Impairment Scale (AIS);
- distance from the spinal cord injury event from 1 to 5 weeks;
- first admission to Montecatone R.I. (in particular to the Critical Care Unit);
- patients with middle-basal hypoventilation;
- patients in partial or continuous mechanical ventilation;
- patients with tracheotomy;
- patients capable of giving meaningful consent;
- collaborating patients.
Exclusion Criteria:
- thoracic trauma with non-drained thoracic fractures and / or pneumothorax and / or hemorrhage;
- pleural effusion;
- significant hemodynamic instability needing amines administration and / or Shock Index > 1.5;
- patients with tracheoesophageal fistulae;
- patients with severe acquired brain injury;
- patients with ongoing sepsis;
- patients with ongoing pregnancy.
Sites / Locations
- Montecatone Rehabilitation Institute S.p.A.
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
T-PEP
IPV
Each T-PEP session includes 10 inspiratory/expiratory cycles, repeated 3 times and interspersed by a pause of about 3 minutes. Each session will be immediately followed by bronchoaspiration and/or Mechanical Insufflation-Exsufflation (MI-E). Sessions will take place at least twice a day for a number of days until the attainment of an effective pulmonary ventilation (as detected by thoracic auscultation), then continued for a further 3 days (at least 2 times a day) for the outcome stabilization, as confirmed also by arterial-blood gas test (ABG), spirometry, chest X-ray and chest ultrasound. T-PEP sessions will take place at least 1 hour after meals or nutrition via nasogastric tube. Tracheal cannula will be kept constantly cuffed during the sessions. Ipratropium Bromide treatment will be on place from study entry until at least 4 weeks after the attainment of a stabilized effective pulmonary ventilation.
Each IPV session includes 3 treatment cycles, interspersed with a pause, consisting of a first high-frequency steps, lasting about 5 minutes, immediately followed by a second low-frequency step lasting approximately one minute. Each session will be immediately followed by bronchoaspiration and/or Mechanical Insufflation-Exsufflation (MI-E). Sessions will take place at least twice a day for a number of days until the attainment of an effective pulmonary ventilation (by thoracic auscultation), then continued for a further 3 days (at least 2 times a day) for outcome stabilization, as confirmed by ABG test, spirometry, chest X-ray and chest ultrasound. IPV sessions will take place at least 1 hour after meals or nutrition via nasogastric tube. Tracheal cannula will be kept constantly cuffed during the sessions. Ipratropium Bromide treatment will be on place from study entry until at least 4 weeks, after the attainment of a stabilized effective pulmonary ventilation.